SCHEMBL9830214

SCHEMBL9830214

CCCC(O)c1cccnc1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.53
LMNA P02545 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
GAA P10253 1/20 0.47
CYP51A1 Q16850 6/20 0.46
CFTR P13569 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
GOPC Q9HD26 1/20 0.46
CYP17A1 P05093 1/20 0.44
TSHR P16473 1/20 0.44
TBXAS1 P24557 1/20 0.42
KCNN4 O15554 1/20 0.41
KCNA5 P22460 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL906187 1.00 SMN1; SMN2 (0.53) SMN1; SMN2LMNAL3MBTL1GAACYP51A1
SCHEMBL9629718 0.91 L3MBTL1 (0.51) SMN1; SMN2LMNAL3MBTL1GAACYP51A1
SCHEMBL2012891 0.89 L3MBTL1 (0.50) SMN1; SMN2LMNAL3MBTL1GAACYP51A1
SCHEMBL17607341 0.88 LMNA (0.49) SMN1; SMN2LMNAL3MBTL1GAACYP51A1
SCHEMBL32346286 0.85 LMNA (0.57) SMN1; SMN2LMNAL3MBTL1GAACYP51A1
SCHEMBL21009583 0.85 LMNA (0.57) SMN1; SMN2LMNAL3MBTL1GAACYP51A1
SCHEMBL7952831 0.85 LMNA (0.57) SMN1; SMN2LMNAL3MBTL1GAACYP51A1
SCHEMBL1579049 0.85 LMNA (0.57) SMN1; SMN2LMNAL3MBTL1GAACYP51A1
SCHEMBL10445445 0.84 SMN1; SMN2 (0.50) SMN1; SMN2LMNAL3MBTL1GAACYP51A1
Hydrochloric Acid SCHEMBL5448253 0.83 LMNA (0.55) SMN1; SMN2LMNAL3MBTL1GAACYP51A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119355177-B Detection method and detection kit for multiple tobacco exposure markers in urine 中国疾病预防控制中心环境与健康相关产品安全所 2025-04-08 CN claimed
CN-119715877-A Method for detecting cigarette smoke exposure biomarker based on nanofiber solid phase extraction 东南大学 2025-03-28 CN claimed
CN-110462403-B Diagnostic test for distinguishing smoking status of a subject 菲利普莫里斯生产公司 2024-01-12 CN claimed
CN-115326994-A Method and system for simultaneously analyzing multi-class smoke exposure biomarkers and using method 上海烟草集团有限责任公司 2022-11-11 CN claimed
CN-112724757-A Ionomer coating for eliminating surface charge, preparation method thereof and corresponding coating 徐宁 2021-04-30 CN claimed
US-4996324-A Reacting secondary alcohol with primary alcohol in presence of basic catalyst BASF AKTIENGESELLSCHAFT (DE) 1991-02-26 US claimed
CN-119846125-A Method for detecting tobacco-specific N-nitrosamine components in tobacco 国家烟草质量监督检验中心 2025-04-18 CN disclosed
CN-119355177-B Detection method and detection kit for multiple tobacco exposure markers in urine 中国疾病预防控制中心环境与健康相关产品安全所 2025-04-08 CN disclosed
CN-119715877-A Method for detecting cigarette smoke exposure biomarker based on nanofiber solid phase extraction 东南大学 2025-03-28 CN disclosed
CN-112353791-B Slip-derived therapeutic compounds and methods of use thereof 夸利蒂赫布丘蒂克斯公司 2025-02-25 CN disclosed
US-20250051746-A1 METHODS AND COMPOSITIONS FOR REDUCING BACTERIAL LOAD IN TOBACCO R.J. REYNOLDS TOBACCO COMPANY (US) 2025-02-13 US disclosed
CN-119355177-A Detection method and detection kit for multiple tobacco exposure markers in urine 中国疾病预防控制中心环境与健康相关产品安全所 2025-01-24 CN disclosed
US-12163167-B2 Methods and compositions for reducing bacterial load in tobacco R.J. REYNOLDS TOBACCO COMPANY (US) 2024-12-10 US disclosed
US-20130065905-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-03-14 US disclosed
US-20110178151-A1 COMPOUNDS AND METHODS OF TREATING OBESITY YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) 2011-07-21 US disclosed
US-20110041859-A1 Molecularly Imprinted Polymers Selective for Tobacco Specific Nitrosamines and Methods of Using the Same BRITISH AMERICAN TOBACCO (INVESTMENTS) LIMITED (GB) 2011-02-24 US disclosed
EP-0227057-B1 PROCESS FOR THE PREPARATION OF SUBSTITUTED ALCANOLS IN 1-POSITION BY AROMATIC OR HETEROCYCLIC GROUPS BASF Aktiengesellschaft (DE) 1991-08-21 EP disclosed
US-4996324-A Reacting secondary alcohol with primary alcohol in presence of basic catalyst BASF AKTIENGESELLSCHAFT (DE) 1991-02-26 US disclosed
EP-0227057-A2 Process for the preparation of substituted alcanols in 1-position by aromatic or heterocyclic groups BASF Aktiengesellschaft (DE) 1987-07-01 EP disclosed
US-3969363-A CARDIOVASCULAR DISORDERS CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) 1976-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065905-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE KYNU, KMO, IDO1 SMN1; SMN2 4284/4885LMNA 4548/4885L3MBTL1 3419/4885
US-20110178151-A1 COMPOUNDS AND METHODS OF TREATING OBESITY GPR119, FABP4, LIPC SMN1; SMN2 3157/4885LMNA 2295/4885L3MBTL1 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.